Biogen Korea is strengthening its position in the local spinal muscular atrophy (SMA) market with expanded reimbursement benefit of Spinraza (ingredient: nusinersen), the company said Thursday.Biogen Korea held a press conference at the Conrad Hotel in Yeouido, Seoul, Thursday, to commemorate the ex
In the midst of growing interest in ribonucleic acid (RNA)-based therapies, such as Spinraza (sodium nusinersenate) for spinal muscular atrophy (SMA) and the messenger ribonucleic acid (mRNA) Covid-19 vaccine, a Korean company is trying to become the industry's No. 1 contract manufacturing organizat
Over the past year, 33 global pharmaceutical companies conducted 1,600 clinical trials in Korea, investing over 800 billion won ($596.1 million) in research costs. The amount was up 14.3 percent, compared to a year earlier.The 14.3 percent R&D growth in 2022 was slower than that of 2021, which stood
Handok Pharmaceuticals, which entered the anticancer market for the first time this year, has begun laying the groundwork for a soft landing of its new cancer drugs in Korea.Handok is reportedly running a patient support program to support drug costs for acute myeloid leukemia drug Vyxeos (cytarabin
Helixmith, a Korean biotech firm focusing on gene therapy, is facing potential administrative measures from the Korea Exchange, having repeatedly delayed its capital increase payment deadlines over a span of six months.According to the Financial Supervisory Service's electronic disclosure system, th
The sudden proliferation of bed bugs in cities such as Daegu and Incheon has now reached Seoul, a capital with a population of 9.7 million people, and this is leading to a surge in demand for insect repellents.According to Dongsung Pharmaceutical, sales of their repellent Biokill in October have sky
Hanmi Pharm's cumulative sales in the first nine months of 2023 posted a record high of 1.1 trillion won ($810 million) on the back of robust prescription drug sales growth, the company said on Wednesday.If this revenue growth trend continues, the company’s annual sales are expected to set a new hig
iNtRON Biotechnology said it has signed a conditional license agreement with Basilea Pharmaceutical, a Switzerland-based multinational pharmaceutical company, prior to the main technology transfer agreement for SAL200, iNtRON's antibacterial bio-drug candidate. iNtRON had signed a technology transfe
GC Pharma announced Wednesday that it has submitted an application for item permission for an anthrax vaccine, GC1109, co-developed with the Korea Disease Control and Prevention Agency (KDCA), to the Ministry of Food and Drug Safety (MFDS).GC1109 uses gene recombination technology to create the Prot
Dong-A ST announced Tuesday in a public filing that its operating profit for the third quarter decreased 7.7 percent year-on-year to 13.1 billion won. Revenue for the third quarter was 15.2 billion won, down 5.1 percent from 15.83 billion won in the same period of the previous year, and net income w
Prostate cancer drug Xtandi (enzalutamide), in combination with androgen deprivation therapy (ADT) to treat patients with metastatic hormone-sensitive prostate cancer (mHSPC), will see its reimbursement status change from selective to essential starting next month.After winning approval for treating
Merck Life Science said it signed a memorandum of understanding (MOU) with Daewoong Pharmaceutical to enhance AI-based new drug development.The strategic partnership aims to apply AI in the entire lifecycle of drug development.Under the accord, Daewoong will employ Merck's products to identify, vali
KL& Partners, a Korean private equity firm, is in advanced talks to acquire Boryung Biopharma for an undisclosed sum.If the deal is finalized, it will mark approximately nine months since Boryung Biopharma was first put up for sale in February.According to industry sources, KL& Partners Consortium w
Samil Pharmaceutical announced Monday that it has signed an MOU with Aptar Pharma, a multinational company headquartered in the U.S., to secure competitiveness in the global eye drops business. The MOU was signed at the Convention on Pharmaceutical Ingredients (CPHI) 2023 last week in Barcelona, Spa
When treating rheumatoid arthritis, establishing insurance coverage guidelines regarding transitions between Janus kinase (JAK) inhibitors is urgently needed, a local rheumatology expert said. Professor Lee Sang-heon of the Rheumatology Department at Konkuk University Hospital spoke on the latest tr
Yuhan Corp. has recently revealed the success of the MARIPOSA clinical trial for Leclaza, its third-generation EGFR tyrosine kinase inhibitor (TKI). This development has sparked interest in whether it will mark the first global introduction of a homegrown anticancer drug.Professor Cho Byoung-chul, h
Barcelona, Spain -- A Korean company received high interest from overseas buyers at the world's largest pharmaceutical and biotechnology fair, CPHI Worldwide 2023, held in Barcelona, Spain, from Tuesday to Thursday.Alteogen, which has recombinant hyaluronidase (ALT-B4) technology, is the company. It
BARCELONA, Spain -- Daewoong Pharmaceutical, which participated in the world's largest pharmaceutical and bio exhibition, CPHI Worldwide 2023, showed confidence in the export competitiveness of homegrown P-CAB medications.In the CPHI 2023, held in Barcelona, Spain, from Tuesday to Thursday, Daewoong
Innovative medical technologies, such as digital treatment devices and diagnostic aids using artificial intelligence, have been decided to receive insurance benefits.The Ministry of Health and Welfare deliberated and approved the “Plan for Medical Benefits for Digital Therapeutic Devices and AI Inno
ICURE, a Korean biopharmaceutical company, has signed an export agreement with ANDK, a U.K.-based pharmaceutical trading company, to supply local anesthetics Plaster and Cataplasma in the Middle East and North Africa (MENA) region, including Kuwait, the UAE, and Egypt.ICURE specializes in the develo